Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

Monopar Therapeutics Inc. (NASDAQ:MNPR) saw a significant increase in short interest in December. As of December 15th, there was short interest totaling 822,858 shares, an increase of 62.2% from the November 30th total of 507,439 shares. Currently, 15.5% of the shares of the stock are sold short. Based on an average daily volume of 181,013 shares, the days-to-cover ratio is currently 4.5 days. Based on an average daily volume of 181,013 shares, the days-to-cover ratio is currently 4.5 days. Currently, 15.5% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MNPR shares. Chardan Capital boosted their target price on shares of Monopar Therapeutics from $85.00 to $100.00 and gave the stock a “buy” rating in a research note on Sunday, November 9th. Leerink Partners assumed coverage on Monopar Therapeutics in a report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price on the stock. Jones Trading upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 10th. Wall Street Zen raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 14th. Finally, Oppenheimer set a $115.00 price target on Monopar Therapeutics and gave the company an “outperform” rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $106.20.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AlphaQuest LLC boosted its position in Monopar Therapeutics by 8.5% in the third quarter. AlphaQuest LLC now owns 1,935 shares of the company’s stock valued at $158,000 after buying an additional 151 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets raised its position in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Monopar Therapeutics in the second quarter worth approximately $34,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after acquiring an additional 1,821 shares during the period. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Trading Down 2.8%

Shares of NASDAQ:MNPR traded down $2.01 on Friday, hitting $68.77. The company had a trading volume of 617,752 shares, compared to its average volume of 187,662. The stock has a market cap of $459.59 million, a price-to-earnings ratio of -19.99 and a beta of 1.46. Monopar Therapeutics has a 1-year low of $21.00 and a 1-year high of $105.00. The stock has a 50 day moving average price of $79.47 and a 200 day moving average price of $60.08.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Sell-side analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.